Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Liabilities and Shareholders Equity (2016 - 2025)

iBio (IBIO) has disclosed Liabilities and Shareholders Equity for 15 consecutive years, with $64.4 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 196.78% to $64.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $170.8 million through Dec 2025, up 36.56% year-over-year, with the annual reading at $23.2 million for FY2025, 19.31% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $64.4 million at iBio, roughly flat from $64.2 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $147.0 million in Q2 2021, with the low at $19.1 million in Q1 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $68.2 million, with a median of $51.0 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 237.98% in 2021, then crashed 61.91% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $126.4 million in 2021, then crashed by 59.03% to $51.8 million in 2022, then crashed by 34.32% to $34.0 million in 2023, then crashed by 36.23% to $21.7 million in 2024, then surged by 196.78% to $64.4 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $64.4 million, $64.2 million, and $23.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.